Compare Crispr Therapeutics AG (CRSP) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Motorola Solutions Inc — how do they compare? Crispr Therapeutics AG trades at $52.89 (market cap $4.88B), while Motorola Solutions Inc trades at $445.43 (market cap $74.00B). The key difference: Motorola Solutions Inc is far larger — about 15.2× Crispr Therapeutics AG's market cap, and Motorola Solutions Inc pays a 1.08% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Motorola Solutions Inc for 100 Days on average.
| CRSP | MSI | |
|---|---|---|
Market Cap | $4.88B | $74.00B |
Volume | 2,861,747 | 722,147 |
Sector | Health | Technology |
52-Week High | $74.92 | $491.24 |
52-Week Low | $44.34 | $363.83 |
Typical Hold Time | 77 Days | 100 Days |
Enterprise Value | $3.30B | $82.90B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Motorola Solutions (MSI) trades at $448.48, down 1.72% on the day, amid a bearish technical signal. The company shows strong fundamentals with revenue growth to $11.68B in 2025 and a record $15.6B backlog. Recent acquisitions like D-Fend Solutions and a $139M Louisiana public safety contract highlight expansion in security and AI-driven solutions. Earnings have consistently beaten estimates, with Q2 2026 EPS of $4.41 surpassing the $3.85 expectation. However, cash flow trends show significant investing outflows for growth initiatives.
The outlook remains positive given analyst consensus with a $525.86 price target and 70.59% buy ratings, though risks include high valuation multiples and increased debt levels from acquisitions. The stock's current bearish technical stance may present a buying opportunity if fundamentals continue to strengthen, but investors should monitor cash flow sustainability and integration of recent purchases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
